Published in Hum Gene Ther on May 01, 2003
In vivo gene delivery by embryonic-stem-cell-derived astrocytes for malignant gliomas. Neuro Oncol (2008) 1.62
Mutant sodium channel for tumor therapy. Mol Ther (2009) 1.22
Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models. Neuropathology (2012) 0.84
Herpes simplex virus type 1/adeno-associated virus hybrid vectors. Open Virol J (2010) 0.75
Herpes Virus Amplicon Vectors. Viruses (2009) 0.75
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol (2008) 19.86
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (2002) 15.36
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol (2002) 8.62
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res (2003) 8.06
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res (2006) 6.91
Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell (2011) 6.43
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38
Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther (2005) 6.04
Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell (2002) 5.11
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res (2007) 4.99
microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res (2008) 4.81
Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res (2006) 4.80
Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med (2013) 4.74
Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res (2008) 4.64
Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron (2007) 4.47
Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov (2013) 4.35
Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med (2012) 4.11
Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun (2011) 4.07
Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron (2007) 3.98
Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol (2004) 3.74
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol (2011) 3.66
A multigene predictor of outcome in glioblastoma. Neuro Oncol (2009) 3.57
Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem (2005) 3.54
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (2010) 3.43
Selective deletion of Bdnf in the ventromedial and dorsomedial hypothalamus of adult mice results in hyperphagic behavior and obesity. J Neurosci (2007) 3.35
A secreted luciferase for ex vivo monitoring of in vivo processes. Nat Methods (2008) 3.31
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet (2013) 3.19
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol (2008) 2.75
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A (2006) 2.72
The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol (2004) 2.66
A highly sensitive assay for monitoring the secretory pathway and ER stress. PLoS One (2007) 2.63
MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell (2010) 2.59
miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell (2008) 2.57
Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst (2007) 2.46
Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res (2006) 2.42
Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol (2002) 2.39
Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res (2006) 2.35
Whole-slide imaging digital pathology as a platform for teleconsultation: a pilot study using paired subspecialist correlations. Arch Pathol Lab Med (2009) 2.30
Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol (2011) 2.27
Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol (2004) 2.21
MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res (2009) 2.11
Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol (2003) 2.08
Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol (2009) 2.06
TorsinA in the nuclear envelope. Proc Natl Acad Sci U S A (2004) 2.06
BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One (2011) 2.04
Case records of the Massachusetts General Hospital. Case 8-2014. A 29-year-old man with headache, vomiting, and diplopia. N Engl J Med (2014) 2.01
Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol (2010) 1.98
DNA global hypomethylation in squamous cell head and neck cancer associated with smoking, alcohol consumption and stage. Int J Cancer (2007) 1.97
Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther (2011) 1.96
Viral vectors for gene delivery to the nervous system. Nat Rev Neurosci (2003) 1.86
The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J Neurosci (2009) 1.85
Spindle cell oncocytoma of the adenohypophysis: report of two cases. Acta Neuropathol (2005) 1.81
Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol (2011) 1.80
TorsinA binds the KASH domain of nesprins and participates in linkage between nuclear envelope and cytoskeleton. J Cell Sci (2008) 1.80
Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. Mol Ther (2003) 1.78
TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J Neurochem (2002) 1.77
Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. Cancer Res (2010) 1.76
Mutant torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia cells. Proc Natl Acad Sci U S A (2007) 1.73
Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol (2006) 1.70
Identification of a novel gene (HSN2) causing hereditary sensory and autonomic neuropathy type II through the Study of Canadian Genetic Isolates. Am J Hum Genet (2004) 1.70
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol (2012) 1.65
Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Hum Gene Ther (2003) 1.65
An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res (2005) 1.63
A pseudolikelihood approach for simultaneous analysis of array comparative genomic hybridizations. Biostatistics (2006) 1.62
Microfluidic isolation and transcriptome analysis of serum microvesicles. Lab Chip (2009) 1.61
Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol (2002) 1.61
Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res (2007) 1.60
Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther (2008) 1.59
miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways. Cancer Res (2010) 1.54
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol (2011) 1.53
Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas. Cancer Res (2003) 1.53
NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med (2012) 1.52
Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci U S A (2008) 1.52
Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res (2005) 1.52
Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther (2004) 1.51
Metabolic biotinylation of cell surface receptors for in vivo imaging. Nat Methods (2006) 1.50
Microvesicle-associated AAV vector as a novel gene delivery system. Mol Ther (2012) 1.49
Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Ann Neurol (2005) 1.48
CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer (2004) 1.48
Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell (2002) 1.48
Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Res (2006) 1.47
Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3. Neuro Oncol (2008) 1.47
Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene (2002) 1.45
Emerging functions of microRNAs in glioblastoma. J Neurooncol (2009) 1.44
Dystonia-causing mutant torsinA inhibits cell adhesion and neurite extension through interference with cytoskeletal dynamics. Neurobiol Dis (2005) 1.44
RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer (2012) 1.43
Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer (2013) 1.42
Hypothalamic dysfunction of the thrombospondin receptor α2δ-1 underlies the overeating and obesity triggered by brain-derived neurotrophic factor deficiency. J Neurosci (2014) 1.42
TorsinA in PC12 cells: localization in the endoplasmic reticulum and response to stress. J Neurosci Res (2003) 1.42
AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res (2006) 1.41
Impaired motor learning in mice expressing torsinA with the DYT1 dystonia mutation. J Neurosci (2005) 1.41